Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Bristol-Myers Squibb Director Michael R. McMullen acquired 3,996.367 deferred share units, increasing his beneficial ownership to 14,979.689 units.

Summary

• Michael R. McMullen, a Director of Bristol-Myers Squibb Co (BMY), acquired 3,996.367 Deferred Share Units.
• The transaction occurred on February 1, 2026.
• Each Deferred Share Unit has a price of $55.05.
• Following this transaction, Mr. McMullen beneficially owns a total of 14,979.689 Deferred Share Units.
• These units are convertible into shares of common stock upon settlement, which occurs when Mr. McMullen ceases to be a director or at a previously specified future date.
• The total beneficial ownership includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's acquisition of additional equity, even deferred, indicates continued confidence in the company's long-term prospects.

Positives

• A director increasing their beneficial ownership, even through deferred units, can signal confidence in the company's future prospects.
• The acquisition of 3,996.367 Deferred Share Units at $55.05 per unit represents an investment of approximately $219,976.99 by the director.

Future Outlook

The Deferred Share Units will convert into common stock upon the reporting person ceasing to be a director or at a future date previously specified by the reporting person, indicating a long-term alignment of interests.

Industry Context

StockSavvy.ai notes that insider acquisitions, particularly by directors, are often viewed positively by the market as they can signal management's belief in the company's future performance. This transaction is a routine part of executive compensation structures in the pharmaceutical industry, aligning director incentives with shareholder value over the long term.

Stakeholder Impact

• Shareholders may view this as a positive sign of management's commitment and belief in the company's future, potentially bolstering investor confidence.

Next Steps

• The Deferred Share Units will become settleable and convert into common stock when Michael R. McMullen ceases to be a director or at a future date he previously specified.

Key Dates

Keywords

Bristol-Myers Squibb, BMY, Insider Transaction, Form 4, Deferred Share Units, Director Ownership, Equity Acquisition